Alzheimer's disease lacks effective treatments that address the underlying molecular mechanisms, leading to limited therapeutic options for patients. Current approaches often fail to consider the genetic factors contributing to resilience against the disease observed in some individuals. This gap hinders the development of targeted therapies that could potentially slow or prevent disease progression.

Epoch Biotech is developing patient-inspired treatments for Alzheimer's disease by focusing on the underlying molecular mechanisms identified in resilient individuals with inherited Alzheimer's. By studying these protective mechanisms, the company aims to create targeted therapies that mimic the natural resilience observed in these patients. This approach involves identifying and validating key molecular targets that contribute to neuronal protection and cognitive preservation. The company is working to translate these findings into novel therapeutic interventions designed to address the root causes of Alzheimer's disease and improve patient outcomes.

Identification of protective genetic variants and molecular pathways associated with Alzheimer's resilience.

Development of targeted therapies that modulate key molecular targets to promote neuronal survival and cognitive function.

Patient-derived cellular models to validate therapeutic candidates and predict clinical efficacy.

Preclinical studies to assess the safety and efficacy of novel therapies in relevant disease models.

The primary target audience includes individuals at risk of or diagnosed with Alzheimer's disease, as well as their families and caregivers, and pharmaceutical companies seeking novel therapeutic targets and strategies for Alzheimer's disease.